A phase 1b study of lenvatinib plus pembrolizumab in unresectable hepatocellular carcinoma

Richard S. Finn; Masafumi Ikeda; Andrew X. Zhu; Max W. Sung; Ari David Baron; Masatoshi Kudo; Takuji Okusaka; Masahiro Kobayashi; Hiromitsu Kumada; Shuichi Kaneko; Marc Pracht; K. G Mamontov; Tim Meyer; Kalgi Mody; Tomoki Kubota; Corina E. Dutcus; Kenichi Saito; Abby B. Siegel; Leonid Dubrovsky; Josep M. Llovet

doi:10.1016/s0168-8278(20)30758-3

Related publications

Article2023

A Phase 1b Study of Lenvatinib plus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma: Extended Analysis of Study 116

Masatoshi Kudo, Richard S. Finn, Masafumi Ikeda, Max W. Sung, Ari David Baron, Takuji Okusaka, Masahiro Kobayashi, Hiromitsu Kumada, Shuichi Kaneko, Marc Pracht, Tim Meyer, Satoshi Nagao, Kenichi Saito, Kalgi Mody, Zahra Ramji, Leonid Dubrovsky, Josep M. Llovet

Liver Cancer

Article2020

Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma

Richard S. Finn, Masafumi Ikeda, Andrew X. Zhu, Max W. Sung, Ari David Baron, Masatoshi Kudo, Takuji Okusaka, Masahiro Kobayashi, Hiromitsu Kumada, Shuichi Kaneko, Marc Pracht, K. G Mamontov, Tim Meyer, Tomoki Kubota, Corina E. Dutcus, Kenichi Saito, Abby B. Siegel, Leonid Dubrovsky, Kalgi Mody, Josep M. Llovet

Journal of Clinical Oncology

Article2018

A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC).

Masafumi Ikeda, Max W. Sung, Masatoshi Kudo, Masahiro Kobayashi, Ari David Baron, Richard S. Finn, Shuichi Kaneko, Andrew X. Zhu, Tomoki Kubota, Silvija Kraljevic, Kohei Ishikawa, Abby B. Siegel, Hiromitsu Kumada, Takuji Okusaka

Article2021

68P A phase Ib study of lenvatinib + pembrolizumab (LEN + PEMBRO) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Study 116 follow-up analysis

Masatoshi Kudo, Richard S. Finn, Masafumi Ikeda, Andrew X. Zhu, Max W. Sung, Ari David Baron, Takuji Okusaka, Masahiro Kobayashi, H. Kumada, Shuichi Kaneko, Marc Pracht, Tim Meyer, Satoshi Nagao, Kenichi Saito, Kalgi Mody, Leonid Dubrovsky, Josep M. Llovet

Annals of Oncology

Article2020

A phase Ib study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC).

Andrew X. Zhu, Richard S. Finn, Masafumi Ikeda, Max W. Sung, Ari David Baron, Masatoshi Kudo, Takuji Okusaka, Masahiro Kobayashi, Hiromitsu Kumada, Shuichi Kaneko, Marc Pracht, K. G Mamontov, Tim Meyer, Kalgi Mody, Tomoki Kubota, Corina E. Dutcus, Kenichi Saito, Abby B. Siegel, Leonid Dubrovsky, Josep M. Llovet